Advances in Lung Cancer: Highlights from the 2nd European Lung Cancer Conference
Educational Concepts Group, LLC  
   
Advances in Lung Cancer: Highlights from the 2nd European Lung Cancer Conference
 
 

Introduction
The past few years have seen a deeper and broader understanding of the molecular biology of lung cancer. Such advances continue to be translated into new treatment options and better patient care. The 2nd European Lung Cancer Conference, a joint effort of the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO), presented an in-depth view of molecular, genetic, pharmacogenomic, pathology, and imaging developments related to the understanding and treatment of non-small cell lung cancer (NSCLC). Highlights are presented here.

Featured Content
• Early Stage NSCLC
• NSCLC: Advanced Disease

Editors
David R. Gandara, MD, bio | Giorgio Scagliotti, MD, PhD, bio

Media: Newsletter
Estimated time to complete activity: 1.0 hour | Release date: May 27, 2010 | Expiration date: May 26, 2011

Target Audience
The intended audience for this initiative is medical, surgical, and radiation oncologists, as well as allied oncology healthcare professionals charged with the care of patients with lung cancer.
 
Learning Objectives
Upon completion of this educational program, participants should be better able to:

  • Describe the most current advances for the diagnosis and staging of patients with lung cancer
  • Describe the rationale for the development and integration of new therapeutic approaches in lung cancer
  • Discuss the clinical implications of the results from pivotal clinical trials that have impacted the use of new approaches and strategies for the treatment of NSCLC
  • Review ongoing clinical trial designs of novel surgical, radiotherapeutic, and chemotherapeutic treatment strategies for the management of NSCLC
  • Discuss supportive care issues and side effect management required for patients with lung cancer 

ACCREDITATION INFORMATION

PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION
ACPE

Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Type of activity: Knowledge-based

Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEUs) (UAN 0199-0000-10-021-H01-P).

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period May 27, 2010 through May 26, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.

CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.

ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

ACKNOWLEDGEMENT
The editors wish to thank Java Solis, a paid medical writer, for assistance in writing this document.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Genentech BioOncology & OSI Oncology.

FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.

THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
David R. Gandara, MD
Grants/Research Support
Abbott, BristolMyersSquibb/ImClone, Genentech BioOncology, Lilly,
Merck & Co., Inc., Novartis, Pfizer

Consultant Fees
Amgen Inc., AstraZeneca, Biodesix, Boehringer Ingelheim,
BristolMyers Squibb/ImClone, GlaxoSmithKline, Genentech BioOncology,
Merck & Co., Inc., Novartis, sanofi-aventis Group, Response Genetics

Giorgio Scagliotti, MD, PhD
Honorarium
AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Roche,
sanofi-aventis Group

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC 
1300 Parkwood Circle SE | Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net

Yes, I am interested in viewing the newsletter.
I have read the information above.
Continue Proceed to this newsletter
 
 

This activity is supported by
an educational grant from Genentech BioOncology
& OSI Oncology.

 
 
Get Adobe Reader
©2010 Designed and produced by Educational Concepts Group, LLC. All rights reserved. | Privacy Policy | Hardware/Software/Internet Requirements